Pms-601

Pms-601

SCHEMBL7243345

CCN(CC)C(=O)OCC1CN(C(=O)c2cc(OC)c(OC)c(OC)c2)CCN1C(=O)c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7234243 0.93
SCHEMBL7234315 0.93
SCHEMBL7234201 0.92
SCHEMBL7240616 0.89 ALDH1A1 (0.54)
SCHEMBL7231811 0.87
SCHEMBL10469605 0.86
SCHEMBL10470709 0.84
SCHEMBL10469597 0.84
SCHEMBL7234883 0.83
SCHEMBL7762866 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6531476-B1 Block multiplication of virus within body and restore immune functions by virtue of inhibitory activity toward platelet activating factor UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) 2003-03-11 US claimed
EP-1095029-B1 PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION UNIV PARIS 7 DENIS DIDEROT (FR) 2002-09-18 EP claimed
EP-1095029-A1 PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION UNIVERSITE PARIS 7 - Denis DIDEROT (FR) 2001-05-02 EP claimed
WO-2000001677-A1 PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) 2000-01-13 WO claimed
US-20250000821-A1 METHODS OF USING DIPIVEFRIN Insignis Therapeutics, Inc. 2025-01-02 US disclosed
US-20240358634-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS DOMPÉ FARMACEUTICI S.P.A. (IT) 2024-10-31 US disclosed
US-11969501-B2 Auris formulations for treating otic diseases and conditions DOMPÉ FARMACEUTICI S.P.A. (IT) 2024-04-30 US disclosed
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2024-03-07 US disclosed
US-11918653-B2 Triglyceride otic formulations and uses thereof DOMPÉ FARMACEUTICI S.P.A. (IT) 2024-03-05 US disclosed
US-11793777-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FIRST WAVE BIO, INC. (US) 2023-10-24 US disclosed
US-11744812-B2 Methods of treatment FIRST WAVE BIO, INC. (US) 2023-09-05 US disclosed
US-20230201143-A1 METHODS OF TREATMENT FIRST WAVE BIO, INC. 2023-06-29 US disclosed
US-20220193010-A1 METHODS OF USING DIPIVEFRIN INSIGNIS THERAPEUTICS INC (US) 2022-06-23 US disclosed
US-20220105057-A1 METHODS OF TREATMENT FIRST WAVE BIO, INC. 2022-04-07 US disclosed
US-20220079897-A1 METHODS OF TREATMENT FIRST WAVE BIO, INC. 2022-03-17 US disclosed
US-20220040095-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS DOMPÉ FARMACEUTICI S.P.A. (IT) 2022-02-10 US disclosed
US-6531476-B1 Block multiplication of virus within body and restore immune functions by virtue of inhibitory activity toward platelet activating factor UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) 2003-03-11 US disclosed
EP-1095029-B1 PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION UNIV PARIS 7 DENIS DIDEROT (FR) 2002-09-18 EP disclosed
EP-1095029-A1 PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION UNIVERSITE PARIS 7 - Denis DIDEROT (FR) 2001-05-02 EP disclosed
WO-2000001677-A1 PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) 2000-01-13 WO disclosed